Melanoma Clinical Trials in Michigan

Showing 141-160 of 253 trials

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283

The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups. The second part of the study will test how well ASN003 can control cancer. Subjects will be enrolled into one of three groups. Group 1: metastatic or recurrent melanoma with documented BRAFV600 mutation (n=20 evaluable patients) Group 2: metastatic colorectal cancer (CRC), or advanced non-small cell lung cancer (NSCLC) with documented BRAFV600 mutation (n=14 evaluable patients) Group 3: advanced solid tumors with documented PI3K pathway alterations (PIK3CA mutation or PTEN loss) (n=14 evaluable patients)

NeoplasmsMelanomaColorectal Neoplasm+1 more

Asana BioSciences24 participantsStarted Oct 2016

Los Angeles, California, United States • Tampa, Florida, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPhase 1/283 miles

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

NCT02988817

The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors

Ovarian CancerCervical CancerEndometrial Cancer+5 more

Genmab306 participantsStarted Nov 2016

Phoenix, Arizona, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +38 more locations

Study of ASN003 in Subjects With Advanced Solid Tumors

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Melanoma Trials in Other Cities

Safety Study of SEA-CD40 in Cancer Patients

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Michigan